

Manuscript version: Published Version

The version presented in WRAP is the published version (Version of Record).

Persistent WRAP URL:

<http://wrap.warwick.ac.uk/144628>

How to cite:

The repository item page linked to above, will contain details on accessing citation guidance from the publisher.

Copyright and reuse:

The Warwick Research Archive Portal (WRAP) makes this work of researchers of the University of Warwick available open access under the following conditions.

This article is made available under the Creative Commons Attribution 4.0 International license (CC BY 4.0) and may be reused according to the conditions of the license. For more details see: <http://creativecommons.org/licenses/by/4.0/>.



Publisher's statement:

Please refer to the repository item page, publisher's statement section, for further information.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk

An *ex vivo* cystic fibrosis model recapitulates key clinical aspects of chronic *Staphylococcus aureus* infection

Esther Sweeney^{1,*}, Niamh E. Harrington¹, Alicia G. Harley Henriques^{1†}, Marwa M. Hassan^{1,2†}, Branagh Crealock-Ashurst¹, Alan R. Smyth³, Matthew N. Hurley⁴, María Ángeles Tormo-Mas⁵ and Freya Harrison^{1,*}

Abstract

Staphylococcus aureus is the most prevalent organism isolated from the airways of people with cystic fibrosis (CF), predominantly early in life. Yet its role in the pathology of lung disease is poorly understood. In mice, and many experiments using cell lines, the bacterium invades cells or interstitium, and forms abscesses. This is at odds with the limited available clinical data: interstitial bacteria are rare in CF biopsies and abscesses are highly unusual. Bacteria instead appear to localize in mucus plugs in the lumens of bronchioles. We show that, in an established *ex vivo* model of CF infection comprising porcine bronchiolar tissue and synthetic mucus, *S. aureus* demonstrates clinically significant characteristics including colonization of the airway lumen, with preferential localization as multicellular aggregates in mucus, initiation of a small colony variant phenotype and increased antibiotic tolerance of tissue-associated aggregates. Tissue invasion and abscesses were not observed. Our results may inform ongoing debates relating to clinical responses to *S. aureus* in people with CF.

DATA SUMMARY

The authors confirm all supporting data, code and protocols have been provided within the article or through supplementary data files.

INTRODUCTION

Staphylococcus aureus is currently the most prevalent pathogen isolated from the airways of people with cystic fibrosis (CF) [1]. Historically, it has been associated predominantly with paediatric pulmonary infection [2], yet the most recent data shows that ~50% of even the oldest patients are now colonized [3]. The presence of *S. aureus* in the respiratory tract varies considerably geographically and over time, and although prevalence appears to decrease with age [4] MRSA is most prevalent between 10–30 year olds [3]. Determining the difference between colonization and infection is both

important and difficult. Nasal carriage of *S. aureus* among children with CF is common: Stone *et al.* [5] reported that 52.4% of the infants they studied harboured the organism. However, relatively high carriage rates in healthy children have also been recorded [6]. Further, expectorate is difficult to collect from infants, so samples are usually collected by oropharyngeal swab, but the presence of organisms in the upper respiratory tract is not always indicative of lower airway infection [7, 8].

Moreover, the association of *S. aureus* with progressive lung disease – as measured by worsening lung function and the development of subsequent infection by the chronic CF pathogen *Pseudomonas aeruginosa* – is unclear [9]. *S. aureus* is able to rapidly adapt to and persist in the CF lung environment [10], and worsening lung condition has been associated with the formation of *S. aureus* small colony variants (SCVs) [11]. SCVs are known to remain in the lung longer than WT

Received 22 January 2020; Accepted 12 October 2020; Published 13 November 2020

Author affiliations: ¹School of Life Sciences, University of Warwick, Coventry, CV4 7AL, UK; ²Department of Pathology and Infectious Diseases, School of Veterinary Medicine, University of Surrey, Guildford, UK; ³Division of Child Health, Obstetrics and Gynecology, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK; ⁴Paediatric Respiratory Medicine, Nottingham Children's Hospital, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK; ⁵Instituto de Investigación Sanitaria La Fe, Avenida Fernando Abril Martorell, 106 Torre A Lab. 6.13, 46026 Valencia, Spain.

***Correspondence:** Esther Sweeney, e.sweeney@warwick.ac.uk; Freya Harrison, f.harrison@warwick.ac.uk

Keywords: 3Rs; antimicrobial resistance; biofilm; chronic infection; Cystic fibrosis; small colony variant.

Abbreviations: abx, antibiotic; BAL, bronchoalveolar lavage; CF, cystic fibrosis; c.f.u, colony forming units; DMEM, Dulbecco's Modified Eagle Medium; EVPL, *ex vivo* pig lung; LB, lysogeny broth; MIC, minimum inhibitory concentration; MRSA, methicillin resistant *Staphylococcus aureus*; MSA, mannitol salt agar; MSSA, methicillin resistant *Staphylococcus aureus*; PBS, phosphate buffered saline; PCR, polymerase chain reaction; PK, pharmacokinetic; SCFM, synthetic CF sputum medium; SCV, small colony variant; UV, Ultraviolet.

†These authors contributed equally to this work

Six supplementary figures and two supplementary tables are available with the online version of this article.

bacterial cells [12] and demonstrate increased antimicrobial resistance [13]. In studies of bronchoalveolar lavage (BAL) fluid from children aged 0–7 years, both Gangell *et al.* and Sagel *et al.* [14, 15] found that positive *S. aureus* culture was linked to a higher degree of airway inflammation, as measured by increased neutrophil count and IL-8. In another study, lung damage (bronchiectasis) in early CF was recorded by CT scan and *S. aureus* was the most commonly isolated organism [16]. Conversely, in adult CF patients, *S. aureus* infections, in the absence of *P. aeruginosa*, are a marker of milder disease [1]. There is also an indication that methicillin-sensitive *S. aureus* may inhibit *P. aeruginosa*, thus delaying lung disease progression [17]. The evidence that early *S. aureus* infection worsens prognosis for CF patients remains conflicting and warrants further study [3, 18].

The lack of understanding regarding the role of *S. aureus* in the development of lung disease in CF has led to debate over the use of anti-staphylococcal prophylaxis early in life. Studies by Ratjen *et al.* and Stutman *et al.* [19, 20] linked the use of broad-spectrum antibiotics to an increase in *P. aeruginosa* isolation. However, a recent Cochrane review [21] showed no effect of anti-staphylococcal prophylaxis on *P. aeruginosa* colonization at 3–4 years. There was a suggested trend towards higher rates of *P. aeruginosa* at 4–6 years but as the studies reviewed did not last more than 6 years, conclusions about the long-term effects of prophylaxis could not be drawn. A pragmatic randomized controlled trial is currently in progress (<http://www.cfstart.org.uk>).

In addition to the lack of clarity over the clinical consequences of *S. aureus* colonization, there is also a gap in our mechanistic understanding of the microbiology of *S. aureus* in CF. The interaction of *S. aureus* with the pulmonary airway in CF, and its subsequent role in pathogenesis, is not clearly documented. CF epithelial cells have been shown to have an increased abundance of aGM1, a receptor that binds *S. aureus* and *P. aeruginosa*, compared with WT epithelia [22], and an *in vitro* study by Schwab *et al.* demonstrated that bacterial adherence to a bronchial epithelial cell line was significantly greater for CF *S. aureus* isolates than non-CF [23]. McKenney *et al.* also show aggregates of *S. aureus* are visible on the surfaces of bronchial sections from children with CF [24]. Yet, the only other study we found with direct evidence of *S. aureus* infection in human biopsy specimens, demonstrated that *S. aureus* did not adhere to the airway epithelium but was found aggregating within the mucus [25]. Furthermore, these authors cited several studies reporting an ability of *S. aureus* to bind mucins [26, 27]. It is obvious that better understanding of just how *S. aureus* colonizes the airway in CF is required, as there are unambiguous data on the underlying mechanisms of pathogenesis and virulence, and the influence of *S. aureus* on subsequent infection by other micro-organisms.

Mice are the most commonly used animal model of pulmonary infection in CF. Mouse models have been used to identify virulence-related genes in pathogens and to test novel therapeutic agents aimed at reducing inflammation or infection [28]. However, mouse models present a number of

Impact Statement

Chronic bacterial infection is one of the main causes of declining lung function and morbidity in people with cystic fibrosis (CF). *Staphylococcus aureus* is the most prevalent organism isolated from the airways of infants with CF. Yet its overall role in the pathogenesis of pulmonary disease is poorly understood. More accurate, high throughput models of CF lung infection are necessary to explore the interactions between *S. aureus* and host in this context. *In vitro* studies cannot accurately replicate chronic disease characteristics, such as the presence of small colony variants, and animal models also do not represent features of clinical disease. Mice, in particular, are not readily colonized by *S. aureus* and when an infection is established it leads to the formation of abscess, a phenomenon not observed in the human CF lung. Here we show an existing *ex vivo* pig lung model of CF infection supports the growth of *S. aureus* and that *S. aureus* demonstrates clinically significant characteristics, including appearance of small colony variants, increased antibiotic tolerance and preferential growth as aggregates in mucus.

challenges. In particular, mice do not develop spontaneous *P. aeruginosa* endobronchial infection, suppurative lung disease and mucus plugging of the airways, that are fundamental characteristics of human CF progression [29]. *S. aureus* does not appear to readily colonize the airways of mice or produce an inflammatory response, even when clinical strains are used, in the presence of mucus [30]. Furthermore, *S. aureus* forms severe abscess-like lesions in the mouse lung [31]. When lung abscess does occur in humans, *S. aureus* is the most commonly isolated organism [32]. However, lung abscess is rare in children [33] and even more so in people with CF: since the advent of neonatal screening and survival past infancy, abscesses are almost never observed in the CF population [34–36].

We previously developed a clinically relevant, high throughput model of chronic bacterial infection in CF. By combining sections of porcine bronchiole (obtained post-slaughter from a commercial abattoir) with a synthetic CF sputum medium (SCFM) [37] we have shown that we can study another key CF pathogen, *P. aeruginosa*, in a physicochemical environment similar to that present *in vivo* [38–40]. The use of CF-like growth medium combined with animal tissue with a greater structural, chemical and immunological similarity to human lung [41] means that our model is likely to facilitate a more human-like pathology of *S. aureus* than that observed in mouse models or *in vitro* studies. Using clinical reference strains and CF isolates of *S. aureus*, we can now demonstrate that in a CF-like environment, *S. aureus* shows non-invasive pathology. Bacteria grow as aggregates associated with the surface of bronchioles and in the surrounding artificial

sputum, without the formation of abscesses or other significant ultrastructural changes to tissue. In fact, we report a potential preference for aggregation in the surrounding mucus rather than growth associated with the bronchiolar surface. We also report the appearance of sub-populations of SCVs. Our work is consistent with *S. aureus* adopting a ‘persister’ rather than ‘invader’ strategy in CF. This stands in marked contrast to the pathology of this species in mouse and cell-culture infection models, and underlines the importance of selecting models that reflect host–pathogen interactions more closely, in order to reliably study the role of specific bacteria in clinical disease progression. A better understanding of *S. aureus* pathology in the highly idiosyncratic environment of the CF lungs will inform optimized clinical responses to positive *S. aureus* cultures.

METHODS

Bacterial strains

USA300LAC Los Angeles County clone (JE2, BEI resources) was used as an example of a well-documented clinical strain. In total, 18 *S. aureus* strains isolated from nine people with CF at Hospital Universitari i Politècnic La Fe were included as exemplars of CF-associated strains. The strains used in this work were extracted for diagnostic purposes and sent to the microbiology service for routine analysis. Once analysed, and instead of being discarded as usual, the strains were grown in tryptic soy broth and kept in glycerin. We chose isolates that represented a range of patient clinical presentation and bacterial phenotypes (e.g. weak or strong biofilm formation as measured by *in vitro* attachment assays, and isolates from patients during periods of stable presentation and episodes of acute exacerbation) (Table S1, available in the online version of this article).

Media and culture conditions for growth in the ex vivo pig lung (EVPL) model

For use in the lung model, bacterial stocks were grown overnight at 37 °C on lysogeny broth (LB) agar. SCFM was prepared according to Palmer *et al.* [37] with the modification that we removed glucose and supplemented with 20 µg ml⁻¹ ampicillin. Our previous work suggested that glucose facilitated the growth of endogenous bacteria present in the lungs and that ampicillin helped to limit the growth of any resident bacteria in the lung that remained after sterilization [38]. We selected a concentration of ampicillin that provided the best possible coverage against endogenous populations but was sub-inhibitory for the *S. aureus* strains used (confirmed by standard MIC testing at the time of collection).

The EVPL model was adapted from our group’s previous work [38, 39], which in turn built on prior use of pig lungs for non-CF studies [42]. Briefly, lungs were collected from a local butcher (Steve Quigley and Sons, Cublington, Warwickshire, UK) as soon as possible following abattoir delivery, and processed immediately upon arrival at the laboratory. Previous antibiotic administration history of the pigs is not known, but use of antibiotics as growth promoters

is banned in the EU, so use is restricted to prophylaxis and mass medication of herds only when infection is suspected. Approximately 5 mm² sections of bronchiolar tissue were dissected from the lung under sterile conditions. During dissection the sections were washed three times with a 1:1 mix of RPMI 1640 and Dulbecco’s Modified Eagle Medium (DMEM) (Sigma-Aldrich), supplemented with 50 µg ml⁻¹ ampicillin, and then rinsed once in sterile SCFM without ampicillin supplementation. Bronchiolar samples were transferred to a clean petri dish and sterilized under a UV lamp for 5 min. Previous work has shown that tissue damage as a result of UV sterilization is minimal (not visible using light microscopy)

[39]. Samples were transferred to 24-well tissue culture plates: each well contained 400 µl SCFM supplemented with 0.8% w/v agarose to form a soft pad. Tissues were inoculated with the appropriate strain of bacteria using a sterile hypodermic needle (29G). The tip of the needle was lightly touched to the surface of the chosen *S. aureus* colony, and then used to pierce the surface of bronchiolar tissue for inoculation. A sterile needle was used for mock infection in uninfected controls. Then, 500 µl of SCFM+ 20 µg ml⁻¹ ampicillin was added to each well and the plate was sealed with a Breath-Easier membrane (Diversified Biotech). Plates were incubated at 37 °C for up to 7 days and refreshed with 300 µl of SCFM+ 20 µg ml⁻¹ ampicillin at 48 h. Following incubation, tissue was rinsed in 1 ml PBS to remove loosely adhering cells and processed for colony counts and microscopy.

Bacterial load assay

Tissue samples used to assay total bacterial numbers in tissue-associated biofilm were homogenized individually in 1 ml PBS in reinforced metal bead tubes (Fisherbrand) using a FASTPREP 24 5G homogenizer (MP Biomedicals) for 40 s at 4.0 m s⁻¹. Homogenates were serially diluted and aliquots were plated on LB and mannitol salt (MSA) agar (Oxoid, Thermo Scientific) to obtain single colonies. MSA agar is selective for *Staphylococcus* and was used to determine colony numbers of test strains and ensure that negative controls did not contain any *S. aureus* already resident in the lung tissue prior to experimentation. Non-selective LB agar was used to check for contamination or growth of endogenous populations. When the bacterial load in SCFM surrounding the lung tissue was measured, 300 µl of SCFM was taken from each well at the same time as tissue processing and transferred to a sterile Eppendorf tube. Samples were vortexed, serially diluted and plated in the same way as tissue homogenate.

LB plates were incubated aerobically at 37 °C for 18–24 h and MSA plates were incubated in at 37 °C 5% CO₂ for 24 h and then for an additional 48 h at room temperature in ambient CO₂ to allow visualization of slow-growing colonies. Total numbers of *S. aureus* recovered from the complete sample were calculated from tissue and SCFM colony numbers combined.

Microscopy

Replica 5 mm² bronchiolar tissue samples, dissected and inoculated as above, were preserved for haematoxylin and eosin staining. Samples were placed in individual tissue processing cassettes (Simport) and fixed overnight in 10% neutral buffered formalin (NBF) at approximately 20 times w/v. Longitudinal, step sections (100 µm) were prepared for histopathology by an external service (University of Manchester). If samples required storage before transport, they were placed in 70% ethanol and kept at 4°C for up to 7 days. Sections were transported in PBS with residual NBF. In addition, 10 µl samples were taken from the SCFM surrounding lung tissue, diluted 1:10 in PBS and 5 µl drops prepared for Gram stain.

Microscopy was conducted with an Axio scope.A1 light microscope (Carl Zeiss) with AxioCam ERc5S digital camera and images processed in Zen Pro 2.1 Blue edition.

Colony identification

Colonies that were able to grow on MSA plates and ferment mannitol (indicated by yellow pigmentation of colony and surrounding clear zone) were regarded as *S. aureus*. Colony morphology was recorded by digital photography. The identity of colonies that were weak fermenters or small in size was initially confirmed using hydrogen peroxide to test for the production of catalase and then a staphylase assay (Oxoid). If SCVs were suspected, colonies were recovered by aerobic incubation overnight on Columbia Blood Agar and morphology was compared to the originally inoculated parent strain. PCR of large and small colonies from MSA plates was used to verify taxonomic identity. First, we performed colony PCR using *Staphylococcus*-specific primers [43]. Once genus was confirmed, amplification of the 16S-23S rRNA intergenic spacer region and Sanger sequencing was used to confirm that SCVs were *S. aureus* (primers 5'-TGCCAAGGCATC-CACCG-3' and 5'-GGCTGGATCACCTCCTT-3').

Determination of antibiotic susceptibility by microdilution

The MIC of flucloxacillin against a pair of representative MSSA isolates (FQ128 and FQ142) and the standard MSSA control strain, ATCC29213, was determined according to the British Society of Antimicrobial Chemotherapy guidelines for microdilution [44] before examining antibiotic tolerance in the EVPL model. All isolates were from sputum samples collected from people with CF during stable presentation. All three strains demonstrated an MIC of <0.0625 mg l⁻¹ and were sensitive to flucloxacillin, MIC breakpoint for resistance is 0.12 mg l⁻¹ (BSAC Guidelines).

Antibiotic tolerance in the EVPL model

Infected lung bronchioles incubated for 48 h as described above. At 48 h 'pre-dose' tissue samples were homogenized and assayed as above. Biological replicates (four bronchiolar sections for each strain and condition) were challenged with antibiotic: tissue samples were washed in PBS then placed in a

new 24-well plate on agar pads. Thereafter, 500 µl SCFM alone was added for controls and 500 µl SCFM +either 0.25 mg l⁻¹ or 5 mg l⁻¹ flucloxacillin for antibiotic tolerance test samples. Concentrations were calculated from the recorded broth MIC of <0.0625 mg l⁻¹ for the strains tested and the clinical target pharmacokinetic (PK) parameters. The PK parameter for beta lactam efficacy is $T > MIC$ with a target of 50% of dosing interval at a free plasma concentration 4–5×MIC [45]. Then, 5 mg l⁻¹ was included to account for potential protein binding, which is 95% for flucloxacillin [46]. Plates were incubated at 37°C. At 4 and 24 h post-dose, treated tissues were washed in PBS to prevent any antibiotic carryover, and all samples homogenized and plated as described above. The bacterial loads in non-antibiotic and antibiotic treated tissues were compared.

Statistical analysis

All data were analysed using RStudio (Mac OS X 10.6+version 1.0.153) (RStudio, <https://www.rstudio.com>) using linear models followed by ANOVA and post-hoc Tukey HSD tests where appropriate, or using Kruskal–Wallis tests, as specified in the text.

RESULTS

Clinical strains of *S. aureus* are able to colonize EPVL

Data taken from preliminary experiments (Fig. 1) showed that bacterial load (c.f.u.) recovered at 48 h was similar for a large range of *S. aureus* CF clinical isolates, and comparable to Los Angeles County clone of USA300LAC, a methicillin-resistant (MRSA) clinical isolate known to form biofilm [47]. Table S1 shows details of CF isolates. Samples were taken from people presenting either with acute exacerbation or in a stable condition (defined as chronic isolates). Isolates were grouped randomly and tested on three separate occasions. In each case, lung samples were dissected from a single lung. Differences in growth were distinguishable between strains (ANOVA, $F_{2,40}=1.9$, $P=0.02$) but post hoc analyses showed no significant difference between any CF isolate and USA300LAC (RStudio, script available on request). The median values for *S. aureus* load recovered at 48 h were 1.64×10^5 , 3.64×10^5 and 6.1×10^5 c.f.u. respectively for lungs 1–3. Growth on Staphylococcal selective media (MSA) was only observed on one of the uninfected controls (Fig. 1a).

S. aureus growth in association with bronchiolar tissue depends on strain and lung but trends are consistent over time

To verify the reproducibility of *S. aureus* numbers recovered from bronchiolar tissue and the ability to observe differences between strains, triplicate samples of USA300LAC and two clinical strains were inoculated into three further lungs taken from different pigs (Fig. 2) and incubation was extended to 7 days. Clinical isolate FQ151 was compared with FQ184, these strains were chosen as an appropriate example pair as they were both isolated from patients with similar




Fig. 1. Recovery of *S. aureus* following 48 h in the EVPL. Each *S. aureus* isolate was inoculated into four replica bronchiolar sections of tissue (a single pair of lungs was used on each of 3 separate days). Uninfected tissue was used as a control. Samples were destructively sampled at 48 h post-infection. *S. aureus* bacterial load was recovered on selective media (MSA) and is measured as total c.f.u. per lung sample (total c.f.u.). Solid lines indicate median values and the limit of detection is shown as a dashed line, no colonies were observed on plates where data is at the limit of detection. USA300LAC is used as a representative control strain, known to form biofilm. Clinical isolates were supplied by the Instituto de Investigación Sanitaria La Fe (Table S1) and numbers are designated as supplied. Analysis of untransformed data by ANOVA showed statistically significant differences in the bacterial load attained by the different strains ($F_{7,32}=1.90$, $P=0.02$).

demographics, both MRSA strains that form biofilm, and had both demonstrated comparable rates of recovery at 48 h from the same lung (Fig. 1). However, FQ184 was isolated during an acute disease exacerbation and FQ151 during stable presentation (representing chronic infection or colonization) (Table S1). It was therefore hypothesized, that by comparing these two strains, differences between exacerbation-associated strains and those apparently persisting asymptotically may be observed, and, if so, could be further investigated with a larger selection of paired isolates. Fig. 2 shows that USA300LAC was again able to establish in the lung and mean *S. aureus* load recovered at 48 h was 6.8×10^6 c.f.u. Mean yields for clinical strains at 48 h were 3.8×10^6 and 5.5×10^5 c.f.u. for FQ184 and FQ151, respectively. By 7 days no colonies were recovered from tissue taken from one of the three lungs for either clinical strain, and counts for clinical strains in a second lung were below or close to the lower limit of detection. Average c.f.u. counts at day 7 were 4.2×10^3 for USA300LAC, 7.9×10^3 for FQ184 and 8.1×10^3 for FQ151. The data were analysed by ANOVA to test for differences between strains, lungs and days, and interactions between day*lung and strain*lung. Total bacterial load was significantly different once again between strains ($F_{2,40}=12.0$, $P<0.001$) and between lungs ($F_{2,40}=6.03$, $P=0.005$). There was a main effect of day ($F_{1,40}=155$, $P<0.001$) and the magnitude of the drop between 48 h and 7 days did not vary significantly between lungs (day*lung interaction $F_{2,40}=9.5$, $P=0.110$) or between strains (strain*day interaction $F_{2,40}=1.73$, $P=0.190$). Different lungs did, however, affect the growth of the strains differently (lung*strain interaction $F_{4,40}=2.62$, $P=0.049$).

***S. aureus* is visible as aggregates at the airway–tissue interface but does not appear to invade tissue**

Monitoring bacterial load within the model by c.f.u. count shows that the model can maintain a *S. aureus* population at 48 h. In addition, it was important to investigate whether the consistent decline in c.f.u. counts by 7 days was due to the inability of the model to support *S. aureus* or whether adaptation of *S. aureus* within the model prevented sufficient monitoring, for example if cells were growing in strongly adherent biofilm that had not been washed off, or as SCV or persister cells that were difficult to recover on media. Therefore, samples were histologically examined to gain a better understanding of growth characteristics in the model. Replicate samples of the inoculated lung tissue (5 mm², dissected from bronchi, as for original model) were washed in PBS and prepared for microscopy, by longitudinal, step section (100 μm), at 2 and 7 days post-infection. Histopathological staining (Figs 3 and 4) showed bronchial mucosa, represented by mature cartilage. In infected samples there is clear evidence of polymorphonuclear leukocytes and organisms, including, predominantly Gram-positive bacilli. Polymorphonuclear leukocytes and organisms are largely absent from uninfected controls with the exception of a small number of rod-shape organisms (Fig. 3b). Gram-positive bacilli aggregate primarily at the tissue–airway interface of infected lungs and their absence from the uninfected lung, (Figs 3a, b and 4a, b) strongly suggests that they are the *S. aureus* deliberately inoculated into test samples. Lung tissue remained largely intact across all tested isolates, even at 7 days. There was some disruption




Fig. 2. Recovery of an exacerbation vs chronic CF isolate of *S. aureus* in the EVPL. *S. aureus* isolates were inoculated into six replica bronchiolar sections of tissue from each of three independent pairs of lungs, and samples were destructively sampled at 48 h and 7 days post-infection by removing the tissue section from surrounding SCFM and bead beating to release adherent bacteria. *S. aureus* bacterial load was recovered on selective media (MSA) and measured as total c.f.u. per tissue sample (c.f.u.). Triplicate lungs are indicated by point shape, and lines represent mean values. The limit of detection is shown as a dashed line. Colony counts on MSA, for uninfected tissue, were not recorded above the detectable limit at 48 h demonstrating that there was no inherent *S. aureus* presence in the lung tissue prior to inoculation. USA300LAC is used as a representative control strain. CF isolates supplied by the Instituto de Investigación Sanitaria La Fe and numbers are designated as supplied. ANOVA conducted on log-transformed data revealed significant main effects of strain ($F_{1,240}=12.0$, $P<0.001$), lung ($F_{2,40}=6.03$, $P=0.005$) and day, and a significant interaction between lung and strain ($F_{4,40}=2.62$, $P=0.049$). There was no significant interaction between day and lung ($F_{2,40}=9.5$, $P=0.110$) or day and strain ($F_{2,40}=1.73$, $P=0.190$).

of tissue integrity at the surface, illustrated by the presence of fibrinous material (highlighted with *). None of the samples show any evidence of abscess, which would present as a clearly defined, bordered structure. *S. aureus* is present only at the tissue–airway interface and does not appear to demonstrate tight association with tissue in the form of a mature biofilm, although more specific staining for biofilm would be required to confirm this. Replica images confirmed histological presentation (Figs S1–S4).

Evidence of other organisms in some samples, for example rod-shaped cells in the tissue infected with FQ184 at 48 h (arrow, Fig. 3f, $\times 100$ magnification), is likely to be endogenous populations present prior to dissection (healthy lungs are not sterile) or contaminants not removed during sterilization; they are also present in the uninfected control (arrow, Fig. 3b). Interestingly, when other bacteria are present, there appear to be distinct ecological niches within the lung environment with Gram-positive bacilli clustered primarily at or near the surface, and rods present embedded within smooth muscle and connective tissue.

This supports much of the current understanding of the structural architecture of polymicrobial communities and it would be useful to study this further especially as the presence of other bacteria may affect the ability of *S. aureus* to survive and adapt within the model. By day 7, cells in clusters of FQ151 were small and poorly stained, and thus difficult to image (Fig. 4d). This may indicate the cells are no longer viable and explain the lack of colonies recovered on plates (Fig. 2). Although inconclusive, the images appear to suggest that there is still a presence of bacterial cocci in association with the lung tissue at 7 days post-inoculation, despite poor recovery of colonies on selective media. It highlights that sputum sampling and colony count alone cannot reliably determine the presence of *S. aureus* populations that may be viable but non-culturable. It would be useful to further investigate, perhaps with the use of *Staphylococcus aureus* specific fluorescent probes or live dead staining in order to confirm the identity and viability of the cells.




Fig. 3. H and E stain of representative lungs at day 2. Uninfected control (a, b) and 48 h post-inoculation with FQ151 (c, d) FQ184 (e, f) or USA300LAC (g, h). $\times 20$ magnification (a, c, e and g). Highlighted area of interest (rectangle) is shown at $\times 100$ magnification (b, d, f and h). Scale bars represent 50 μm and 10 μm accordingly. Cocci-shaped cells are present in all inoculated tissue at $\times 100$ (d, f and h) but not uninfected control (b) Disruption to bronchiole tissue is also evident in all infected samples (*) less extensive for FQ184 (e) a strain taken during acute exacerbation, but more marked for USA300LAC (g) and not seen in uninoculated control (a) Arrows indicate the presence of rod-shaped bacterial cells in both uninfected (b) and inoculated (f) samples, suggesting the presence of endogenous lung species.

***S. aureus* aggregates in artificial sputum surrounding lung tissue**

Initial experiments (Figs 1 and 2) only recorded bacterial burden recovered from washed tissue pieces. The histology suggests at least some *S. aureus* may be tightly associated

with the tissue in the model and not removed during homogenization. In addition, there is evidence in the literature to suggest *S. aureus* may preferentially bind to mucus plugs in the airways of the CF lung, rather than associating with the tissue surface [25]. Both are possible explanations as to why,




Fig. 4. H and E stain of representative lungs at day 7. Uninfected control (a,b) and 7 days post-inoculation with FQ151 (c, d) FQ184 (e, f) and USA300LAC (g,h). $\times 20$ magnification (a,c,e and g). Highlighted area of interest (rectangle) is then shown at $\times 100$ magnification (b, d, f and h). Scale bars represent $50\ \mu\text{m}$ and $10\ \mu\text{m}$ accordingly. Clusters of cocci-shaped cells are present at or near the tissue–airway interface for all inoculated tissue at $\times 100$ (d, f and h) but not uninfected control (b).

despite presumably being adapted to the lung environment, c.f.u. loads associated specifically with the bronchiolar tissue showed such a marked drop by day 7.

A subset of clinical strains, two MRSA and two MSSA (methicillin-sensitive) strains, were chosen to investigate

growth in the surrounding SCFM, and compared with USA300LAC (Fig. 5). When bacteria were also recovered from the surrounding SCFM and enumerated, the total c.f.u. count from the sample (tissue plus surrounding SCFM) was higher than the c.f.u. count for tissue only (Fig. 5a). Although




Fig. 5. Location of *S. aureus* in the EVPL model 48 h and 7 days: c.f.u. and proportion of c.f.u. recovered from artificial sputum media (SCFM) vs tissue. *S. aureus* isolates were inoculated into six replica bronchiolar sections of tissue from each of three independent pairs of lungs, and samples were destructively sampled at 48 h and 7 days post-infection. Aliquots of the SCFM surrounding each sampled piece of tissue were also assessed for bacterial load. USA300LAC was used as representative control strain and an uninfected lung used as a negative control. Clinical isolates supplied by the Instituto de Investigación Sanitaria La Fe and numbers are designated as supplied. (a) *S. aureus* cell counts recovered on MSA agar from EPVL at 48 h and 7 days. Bacterial load measured as total c.f.u. per tissue, surrounding SCFM or total sample (c.f.u.). Counts were taken from triplicate lungs, indicated by point shape. Non-parametric Kruskal-Wallis tests were used to test for differences in the proportion of bacteria in the surrounding SCFM at 48 h and 7 days. Increases in proportional growth in SCFM were found for strains FQ128 (Chi-squared=7.44, $P=0.006$, $df=1$), FQ140 (Chi-squared=11, $P<0.001$, $df=1$), FQ151 (Chi-squared=7.1, $P=0.008$, $df=1$) and USA300LAC (Chi-squared=12.3, $P<0.001$, $df=1$). FQ142 showed no significant increase in SCFM proportion (Chi-squared=1.2, $P=0.22$, $df=1$). (b) Proportion of total c.f.u. recovered from tissue vs surrounding SCFM at 48 h and 7 days. Line shows equal c.f.u. in SCFM and tissue, for reference. Minimum limit of detection 4.3×10^1 . Linear models on log-log transformed data showed a significant correlation between growth associated with tissue and growth in surrounding SCFM at both time points. (Full details of ANOVA results are given in the Supplementary Material, R^2_{adj} for models testing for effects of lung, strain, c.f.u. lung and strain*c.f.u. lung on c.f.u. in SCFM were 0.50 for 48 h data and 0.36 for day 7 data.

'mucus plugs' do not form in the model, aggregates of *S. aureus* cells were visible in Gram stains of surrounding SCFM at day seven for all strains tested (Fig. S5) and by day 7, a greater proportion of the total bacterial population was consistently found in the surrounding SCFM than in tissue-associated biofilm (Fig. 5b). The four biofilm forming strains all showed a significant increase in the proportion of recoverable cells in the SCFM between 48h and day 7 as measured by the Kruskal–Wallis test (FQ128 $\chi^2=7.44$, FQ140 $\chi^2=11$, FQ151 $\chi^2=7.1$, USA300LAC $\chi^2=12.3$; all P -values ≤ 0.008). FQ142 did not show a significant increase in SCFM proportion between the two time points (Kruskal–Wallis test, $\chi^2=1.2$, $P=0.22$). FQ142 is not a biofilm former (Table S1), and so likely to have a higher proportion already in the SCFM by 48h. SCFM is a minimal media and it is significant that there are viable cells are maintained in the SCFM for 7 days with limited nutrient replenishment, suggesting the addition of lung tissue to the model is an important improvement.

Tissue-associated populations demonstrate phenotypes consistent with chronic infection

The data collected by cell enumeration (Figs 1, 2 and 5), for growth and localization of *S. aureus* in the model, suggest the existence of subpopulations present during chronic infection. These likely comprise aggregates of cells in the mucus and a smaller percentage of tissue or biofilm-associated cells, which may be slow-growing SCVs or non-growing persisters. If this is the case it would be consistent with hypotheses in the literature regarding *S. aureus* infection [48], and we would anticipate that there would be SCVs present in the model and the 'persister' subpopulation would demonstrate increased antibiotic tolerance.

Small colonies (<50% diameter of usual *S. aureus* colonies) were observed on MSA plates after incubation for at least 48h in 5% CO₂ at 37°C for samples taken 7 days post-inoculation. Example colonies were photographed (Fig. S6) and some had weak catalase and coagulase results when tested, weak catalase is indicative of deficient haem production and is associated with SCVs, as is weak coagulase. SCVs were confirmed as *S. aureus* spp. using genus-specific primers (STaG) [43] followed by sequencing of the 16s-23S intergenic region (Table S2).

Antibiotic tolerance of tissue-associated aggregates

Slow-growing or biofilm bacterial populations may be tolerant to antibiotics and implicated in the persistence of chronic infection. Tolerance of tissue-associated aggregates to flucloxacillin was assessed for a pair of clinically isolated MSSAs that were susceptible to flucloxacillin in a standard MIC microdilution and had the same MIC as the control strain ATCC29213 (<0.0625 mg l⁻¹). They were isolated from people who presented asymptotically (without exacerbation) (Table S1). Lung tissue was infected with *S. aureus* and incubated as described above. At 48h, antibiotic test samples were challenged with a single dose of

either 0.25 mg l⁻¹ or 5 mg l⁻¹ (to account for potential protein binding) flucloxacillin; growth control samples were maintained in SCFM alone and uninfected lungs used as a negative control. Tissue was processed at 4 and 24h post-dose and total *S. aureus* load recorded as before (Fig. 6a). As in previous experiments, uninfected control tissues showed no growth on MSA plates. Clinically, bactericidal activity of an antibiotic is regarded as a reduction of 99.9% (>3 log₁₀ decrease) in the c.f.u. ml⁻¹ of the original sample. The data presented in Fig. 6b demonstrates that a mean decrease of >3 log₁₀ was only achieved against FQ142 when challenged with the higher concentration of 5 mg l⁻¹ flucloxacillin for 24h, despite all three strains demonstrating susceptibility in a standard MIC test. For ATCC29213 there was no significant effect of dose (ANOVA, $f_{2,21}=0.2$ $P=0.8$) or dosing interval (ANOVA, $f_{2,21}=1.9$ $P=0.2$) on c.f.u. ml⁻¹. Although there was an overall significant effect of dose on c.f.u. ml⁻¹ for FQ128 (ANOVA, $f_{2,21}=5.8$, $P=0.01$) and FQ142 (ANOVA, $f_{2,21}=7.5$, $P=0.004$), post hoc analysis showed this was not significant for 0.25 mg l⁻¹ (FQ128, $P=0.8$ and FQ142, $P=0.2$) and a mean decrease in c.f.u. ml⁻¹ of >3 log₁₀ was not achieved for either strain at this concentration (Fig. 6b). Dosing interval was found to be significant for FQ128 ($f_{2,21}=7.2$, $P=0.004$) but not for FQ142 ($f_{2,21}=0.03$, $P=0.97$). The fact that the required bactericidal target was not reached for the control strain, ATCC29213, and that the response of the two clinical isolates varied, shows that standard MIC testing may not reliably predict clinical response to antibiotic regimes. There was no significant decrease in bacterial recovery between pre-dose and 24h post-dose when challenged with 0.25 mg l⁻¹ flucloxacillin and FQ142 showed a potential to grow under these conditions, suggesting sub-inhibitory flucloxacillin concentrations could lead to selection for resistance. Furthermore, although 5 mg l⁻¹ flucloxacillin had a significant effect on c.f.u. ml⁻¹ for both clinical strains, it failed to cause a mean decrease in FQ128 c.f.u. ml⁻¹ of >3 log₁₀, suggesting that some strains could tolerate clinically relevant concentrations even when antibiotic protein binding is accounted for. This was a very small sample set, and further investigation is warranted, but, it indicates that maintaining plasma concentrations above the target of 4×MIC may be necessary for effective treatment of *S. aureus* infection in CF.

DISCUSSION

Growth and localization of *S. aureus* in EPVL

There is an apparent contradiction between the usual pathology of *S. aureus* in human CF samples (non-invasive) and in standard laboratory models using cell-culture or mouse lung infections. To address this gap between the clinical norm and standard lab models, we grew a biobank of clinical isolates in an *ex vivo* model of CF lung infection, which carefully mimics human tissue structure and the chemistry of CF lung secretions. *S. aureus* grew with reasonable consistency, both associated with lung tissue, at the airway surface, and as bacterial aggregates in artificial sputum (SCFM) around the tissue. *S. aureus* bioburden was maintained in EPVL over




Fig. 6. Recovery of *S. aureus* clinical isolates from EPVL following flucloxacillin challenge. Each *S. aureus* isolate was inoculated into replica bronchiolar sections of tissue from the same pair of lungs, and incubated as previously described for 48 h. Four replica samples were processed for counting of bacterial load, prior to antibiotic challenge (0 h, pre-dose). Remaining samples were moved to SCFM containing either no antibiotic (circles), 0.25 mg l⁻¹ (triangles) or 5 mg l⁻¹ (diamonds) flucloxacillin and incubated for 4 or 24 h. Uninfected tissue pieces were used as control and processed as infected replica, no colonies were observed on recovery plates for uninfected controls and so c.f.u. was recorded as at the limit of detection (stars). Lines represent mean bacterial load. All isolates were classified as sensitive by standard antibiotic susceptibility testing (MIC < 0.0625 mg l⁻¹). Bactericidal activity, (>3 log₁₀ in c.f.u.) was only observed against FQ142 when challenged with 5 mg l⁻¹ flucloxacillin for 24 h (Fig. 6b, highlighted). Antibiotic dose had no significant effect for ATCC29213 (ANOVA, $f_{2,21}=0.2$, $P=0.8$) for clinical strains there was an overall effect of dose: ANOVA, $f_{2,21}=5.8$, $P=0.01$ and $f_{2,21}=7.5$, $P=0.004$ for FQ128 and FQ142, respectively. However, post hoc analysis revealed there was no significance for either strain when exposed to 0.25 mg l⁻¹ flucloxacillin (FQ128, $P=0.8$ and FQ142, $P=0.2$).

7 days, although tissue-associated c.f.u. numbers were diminished over this period and in general the bacteria showed a preference for growth as aggregates suspended in the SCFM.

Defined biofilm was not investigated in histological samples, although there was evidence of potential biofilm architecture and increased structure in bacterial populations for some samples by 7 days compared to 48 h. Interestingly, we have recently reported that *P. aeruginosa* does demonstrate extensive biofilm growth in the EPVL that can be observed using the same histological staining techniques [40]. This is consistent with the available clinical evidence where extensive biofilms have not been described for *S. aureus* in the CF lung [49], but small, biofilm-like aggregates are reported in the sputum and on the surface of airways [24, 25, 50, 51]. Consistent with growth as aggregates *in vivo*, there is evidence that *S. aureus* switches off the global regulator *agr* in CF [48].

We did not observe interstitial invasion by *S. aureus*. Generally, interstitial bacteria are rarely observed in biopsy samples from people with CF (even if significant interstitial inflammation is observed) and bacteria in the airways are confined in luminal mucus plugs or occasionally attached to defined foci of epithelial erosion; this lack of tissue invasion is consistent with the rarity of bacteremia in people with CF [24, 25, 52–57]. CF lung disease thus presents as bronchiectasis with mucous plugging of small airways. In contrast, microscopy images presented in studies of murine pulmonary *S. aureus* infections typically show abscesses (a cavitating, pus-filled lesion within

the tissue with a defined border: see Fig. 2 in [31] and Fig. 2 in [58], for examples) and lead to chronic pneumonia [59]. Clearly, there are significant differences in *S. aureus* pathology in mouse models versus the highly specialized environment of CF airways as approximated by the *ex vivo* pig lung model.

In light of this, it is significant that our results suggest preferential localization of *S. aureus* in the SCFM surrounding the tissue sections, as opposed to epithelial surface attachment, and we did not observe the appearance of abscess-like structures. *S. aureus* can cause lung abscess in humans – in fact it is one of the most common bacteria isolated from abscesses [60] – but abscesses are almost never observed in people with CF [56, 57]. A specific Pantone-Valentine Leukocidin positive strain of MRSA was associated with invasive, cavitating lung lesions in a CF centre in the USA in the mid 2000s [61], but this is unusual. Other than this specific outbreak, a literature search revealed only five cases of abscess among people with CF, only two of which were associated with *S. aureus*: one patient was co-colonized by *P. aeruginosa* and the other with *P. denitrificans* [34, 62]. It should be noted that abscess formation is associated with the presence of neutrophils, our model uses post-mortem tissue and, therefore, the effect of the host immune response is not observable. In addition, tissue samples in our model are taken only from the bronchi wall and so may not capture abscess formation. However, given the rarity of clinical evidence for invasive *S. aureus* infection in people with CF, induction of abscess formation may not

be clinically important in a CF model. Clinical observations are consistent with a study in which mucus hypersecretion was induced in cultured primary nasal epithelia cells to better mimic conditions in the CF lung: mucus presence led to *S. aureus* cells moving away from the epithelial cell surface and growing in the mucus [25] – as observed in our model.

Chronic infection phenotypes of *S. aureus* in EPVL

The tissue-associated subpopulation exhibited enhanced tolerance to flucloxacillin compared with standard susceptibility assay results. This is likely due to physiological cues from the lung environment and the appearance of a subpopulation of SCVs [11, 13, 63–65] but may also be influenced by the presence of biofilm structure matrix if it is present (which could usefully be explored in future work).

Small colony variants emerged once *S. aureus* isolates were passaged through the EPVL. The phenotypic development of SCVs has been linked to chronic CF infections [63, 64]. The impact of SCVs on virulence and persistence is difficult to study *in vitro*, as they rapidly revert to normal colony morphology when attempts are made to culture them [51], and it usually requires the creation of artificially generated, stable SCVs which may not fully represent those generated by the *in vivo* environment [66]. Notwithstanding these limitations, studies have linked the SCV phenotype with attenuated virulence [67] and a dampened host cytokine response [68, 69] – both changes that are consistent with the adoption of persistence strategy. The ability of the *ex vivo* lung model to cue SCV emergence is likely to be a significant strength of the model, permitting a rapid means to generate this phenotype and allowing more extensive future research into the effects of SCVs. It will be important, however, to tease apart the relative contributions of the presence of tissue and the presence of sub-inhibitory levels of ampicillin on SCV emergence. Since completing this work, we have begun a more extensive investigation of methods to reduce the presence of endogenous bacteria from the lung tissue, and we have found that expedited access to lungs after slaughter allows us to obtain tissue which requires less rigorous control measures. Future experiments using EVPL with different or no antibiotic supplementation will allow us to explore the impacts of tissue and antibiotic presence on microbial physiology.

Population heterogeneity of *S. aureus* *in vivo* and in EVPL

The evidence outlined above is consistent with *S. aureus* growing as phenotypically heterogeneous populations in CF – comprising tissue-associated, biofilm-like aggregates and mucus-embedded aggregates, with the potential presence of SCVs. Persistence, antibiotic tolerance, gene expression and ability to be cultured *in vitro* are likely to differ between these subpopulations, and understanding the differences within heterogeneous populations could improve understanding of virulence mechanisms. If this is the case, the *ex vivo* pig lung model will be valuable in future studies, for the generation of heterogeneous populations that are hard to reproduce in animal and traditional *in vitro* models.

Strengths and limitations of the EVPL model

Our data reinforce the notion that host-specific pathology is an important area of future study, with particular significance for *S. aureus*. Modelling *S. aureus* infection, in any tissue other than human biopsy, is likely to present differences and challenges. It is abundantly clear that both mouse and *in vitro* models fail to capture key features of pathology observed from human clinical data that are revealed by our EVPL model. Consequently, EVPL could fill an important gap in the toolkit for answering crucial questions about the microbiology and clinical impact of *S. aureus* in CF.

There are, of course, some areas where the model could be optimized for future use. Primarily, variability in *S. aureus* bacterial load was considerable. We inoculated tissue sections from single colonies, and not a standardized broth culture, as preliminary work with *P. aeruginosa* in an earlier version of the model showed no significant variation in the number of cells inoculated from single colonies, or the cell numbers recorded at 48 h [39]. Additionally, in CF there is unlikely to be a large burden of colonizing bacteria [70]. Given the differences in the way that *P. aeruginosa* and *S. aureus* grow in the model, starting inoculum may be a more significant determinant of the growth and survival of *S. aureus* and standardizing cell numbers could be important for future developments, for example assessing the impact of antimicrobial agents on viable bacterial burden. More broadly, better data on the variability in *S. aureus* aggregate size between foci of infection within CF lungs, and between patients, would be useful for understanding *S. aureus* pathology. In a study by Hirschhausen *et al.* [59], adaptive changes differed in patients infected with the same *S. aureus* clonal lineage, indicating that individual host factors had an impact on adaption. This is reminiscent of our results, which show significant variability between lungs taken from different pigs (Fig. 2).

We also stress, given the reported intraspecific phenotypic and genetic diversity of bacteria within and between people with CF, and given observed differences in the growth and localization of a pair of isolates taken from stable infection and acute exacerbation (Figs 2–4), future work could usefully explore a larger collection of isolates in more depth.

CONCLUSION

The *ex vivo* lung model is designed to maximize physico-chemical similarity to chronically infected human CF airways. It is also high throughput and inexpensive, and because it uses post-consumer waste from the meat industry, it presents no ethical concerns [38]. Our results from *S. aureus* infection of the *ex vivo* model reveal aspects of chronic CF pathology, which are not captured by existing ‘gold standard’ animal models: aggregation of bacterial cells associated with tissue but also (perhaps predominantly) in mucus; the development of SCVs; and an increase in antibiotic tolerance. The potential preferential binding of *S. aureus* to mucus, and lack of tissue invasion, is a phenomenon that may have clinical relevance,

especially given current questions about the role of *S. aureus* as a CF pathogen and the consequences of trying to remove it.

Funding information

The work was funded by a Medical Research Council New Investigator Research Grant to FH (grant number MR/R001898/1) and by the University of Warwick via AHH's final-year research project. N.E.H. is funded by a PhD studentship from the BBSRC Midlands Integrative Biosciences Training Partnership (MIBTP). The Histology Facility equipment used in this study was purchased with grants from The University of Manchester.

Acknowledgements

We would like to acknowledge the help of Cerith Harries and Caroline Stewart and the use of the media preparation facilities within the School of Life Sciences technical team, and Ian Hands-Portman in the Life Sciences imaging suite, at the University of Warwick. We also thank Peter Walker and the Histology Core Facility at the University of Manchester for histological sample preparation and Dr Irshad Nabi Soomro, Consultant Histopathologist & Honorary Clinical Associate Professor at the Department of Cellular Pathology, Nottingham University Hospitals NHS Trust, for helpful interpretation of histographs. Finally, we thank Amparo Soler at Hospital Universitari i Politecnic La Fe, for the demographics and clinical presentation data of CF patients.

Author contributions

F.H. and E.S. conceived the study. E.S. optimized EVPL for the present work with *S. aureus*, conducted experimental work, analysed data and drafted the manuscript. F.H. developed the EVPL model and contributed to manuscript preparation. N.E.H. conducted experimental work (histological sample preparation and imaging), completed statistical data analysis and contributed to manuscript preparation. A.H.H. and B.C.A. conducted experimental work as part of student projects for the University of Warwick's BSc(Hons) in Biomedical Science and MB ChB, respectively. M.M.H. contributed to the development of EVPL conducted experimental work and edited the manuscript. M.A.T.M. contributed clinical isolates and associated data. A.R.S. and M.N.H. contributed clinical context for the study goals and interpretations, and contributed to manuscript preparation. All authors saw and approved the final manuscript draft.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Ethical statement

All methods were carried out in accordance with institutional and national guidelines and regulations. Sample collection and protocols were approved by the Biomedical Research Committee of Research Institute la Fe (reference 2014/0563). Initial diagnostic plates of sputum samples were not stored and were discarded after strain isolation, and strains were anonymized; thus, according to the provisions of article 24 of Royal Decree 1716/2011 on biomedical research, it was not necessary to request the declaration of compliance with the organic law on data protection, nor informed consent.

References

- Ahlgren HG, Benedetti A, Landry JS, Bernier J, Matouk E *et al*. Clinical outcomes associated with *Staphylococcus aureus* and *Pseudomonas aeruginosa* airway infections in adult cystic fibrosis patients. *BMC Pulm Med* 2015;15:15–67.
- Szafl M, Højby N. Antibiotic treatment of *Staphylococcus aureus* infection in cystic fibrosis. *Acta Paediatr Scand* 1982;71:821–826.
- Cystic Fibrosis Foundation Patient Registry 2018 Annual Data Report. Cystic fibrosis Foundation 2019.
- Hurley MN. *Staphylococcus Aureus in Cystic Fibrosis: Problem Bug or an Innocent Bystander? Breathe (Sheff)*, 14. England; 2018. pp. 87–90.
- Stone A, Quittell L, Zhou J, Alba L, Bhat M *et al*. *Staphylococcus aureus* nasal colonization among pediatric cystic fibrosis patients and their household contacts. *Pediatr Infect Dis J* 2009;28:895–899.
- Fritz SA, Krauss MJ, Epplin EK, Burnham CA, Garbutt J *et al*. The natural history of contemporary *Staphylococcus aureus* nasal colonization in community children. *Pediatr Infect Dis J* 2011;30:349–351.
- Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R *et al*. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. *Pediatr Pulmonol* 1999;28:321–328.
- Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A *et al*. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. *Pediatr Pulmonol* 1996;21:267–275.
- Limoli DH, Hoffman LR. Help, hinder, hide and harm: what can we learn from the interactions between *Pseudomonas aeruginosa* and *Staphylococcus aureus* during respiratory infections? *Thorax* 2019;74:684–692.
- Goerke C, Wolz C. Regulatory and genomic plasticity of *Staphylococcus aureus* during persistent colonization and infection. *Int J Med Microbiol* 2004;294:195–202.
- Wolter DJ, Emerson JC, McNamara S, Buccat AM, Qin X *et al*. *Staphylococcus aureus* small-colony variants are independently associated with worse lung disease in children with cystic fibrosis. *Clin Infect Dis* 2013;57:384–391.
- Kahl BC, Duebbers A, Lubritz G, Haeblerle J, Koch HG *et al*. Population dynamics of persistent *Staphylococcus aureus* isolated from the airways of cystic fibrosis patients during a 6-year prospective study. *J Clin Microbiol* 2003;41:4424–4427.
- Besier S, Smaczny C, von Mallinckrodt C, Krahl A, Ackermann H *et al*. Prevalence and clinical significance of *Staphylococcus aureus* small-colony variants in cystic fibrosis lung disease. *J Clin Microbiol* 2007;45:168–172.
- Gangell C, Gard S, Douglas T, Park J, de Klerk N *et al*. Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. *Clin Infect Dis* 2011;53:425–432.
- Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL *et al*. Impact of *Pseudomonas* and *Staphylococcus* infection on inflammation and clinical status in young children with cystic fibrosis. *J Pediatr* 2009;154:183–188.
- Davis SD, Fordham LA, Brody AS, Noah TL, Retsch-Bogart GZ *et al*. Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. *Am J Respir Crit Care Med* 2007;175:943–950.
- Granchelli AM, Adler FR, Keogh RH, Kartsonaki C, Cox DR *et al*. Microbial interactions in the cystic fibrosis airway. *J Clin Microbiol* 2018;56.
- Wong JK, Ranganathan SC, Hart E, Australian Respiratory Early Surveillance Team for Cystic Fibrosis (ARESTCF). *Staphylococcus aureus* in early cystic fibrosis lung disease. *Pediatr Pulmonol* 2013;48:1151–1159.
- Ratjen F, Comes G, Paul K, Posselt HG, Wagner TO *et al*. Effect of continuous antistaphylococcal therapy on the rate of *P. aeruginosa* acquisition in patients with cystic fibrosis. *Pediatr Pulmonol* 2001;31:13–16.
- Stutman HR, Lieberman JM, Nussbaum E, Marks MI. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. *J Pediatr* 2002;140:299–305.
- Smyth AR, Rosenfeld M. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. *Cochrane Database Syst Rev* 2017;4:Cd001912.
- Imundo L, Barasch J, Prince A, Al-Awqati Q. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. *Proc Natl Acad Sci U S A* 1995;92:3019–3023.
- Schwab UE, Wold AE, Carson JL, Leigh MW, Cheng PW *et al*. Increased adherence of *Staphylococcus aureus* from cystic fibrosis lungs to airway epithelial cells. *Am Rev Respir Dis* 1993;148:365–369.
- McKenney D, Pouliot KL, Wang Y, Murthy V, Ulrich M *et al*. Broadly protective vaccine for *Staphylococcus aureus* based on an in vivo-expressed antigen. *Science* 1999;284:1523–1527.

25. Ulrich M, Herbert S, Berger J, Bellon G, Louis D et al. Localization of *Staphylococcus aureus* in infected airways of patients with cystic fibrosis and in a cell culture model of *S. aureus* adherence. *Am J Respir Cell Mol Biol* 1998;19:83–91.
26. Shuter J, Hatcher VB, Lowy FD. *Staphylococcus aureus* binding to human nasal mucin. *Infect Immun* 1996;64:310–318.
27. Sanford BA, Thomas VL, Ramsay MA. Binding of staphylococci to mucus in vivo and in vitro. *Infect Immun* 1989;57:3735–3742.
28. Bragonzi A. Murine models of acute and chronic lung infection with cystic fibrosis pathogens. *Int J Med Microbiol* 2010;300:584–593.
29. Lavelle GM, White MM, Browne N, McElvaney NG, Reeves EP. Animal models of cystic fibrosis pathology: phenotypic parallels and divergences. *Biomed Res Int* 2016;2016:5258727.
30. Cressman VL, Hicks EM, Funkhouser WK, Backlund DC, Koller BH. The relationship of chronic mucin secretion to airway disease in normal and CFTR-deficient mice. *Am J Respir Cell Mol Biol* 1998;19:853–866.
31. Cigana C, Bianconi I, Baldan R, De Simone M, Riva C et al. *Staphylococcus aureus* impacts *Pseudomonas aeruginosa* chronic respiratory disease in murine models. *J Infect Dis* 2018;217:933–942.
32. Kuhajda I, Zarogoulidis K, Tsigogianni K, Tsavlis D, Kioumis I et al. Lung abscess-etiology, diagnostic and treatment options. *Ann Transl Med* 2015;3:183.
33. Patradoon-Ho P, Fitzgerald DA. Lung abscess in children. *Paediatr Respir Rev* 2007;8:77–84.
34. Canny GJ, Marcotte JE, Levison H. Lung abscess in cystic fibrosis. *Thorax* 1986;41:221–222.
35. Hurley MN, McKeever TM, Prayle AP, Fogarty AW, Smyth AR. Rate of improvement of CF life expectancy exceeds that of general population-observational death registration study. *J Cyst Fibros* 2014;13:410–415.
36. Andersen DH. Therapy and prognosis of fibrocystic disease of the pancreas. *Pediatrics* 1949;3:406–417.
37. Palmer KL, Aye LM, Whiteley M. Nutritional cues control *Pseudomonas aeruginosa* multicellular behavior in cystic fibrosis sputum. *J Bacteriol* 2007;189:8079–8087.
38. Harrison F, Diggle SP. An ex vivo lung model to study bronchioles infected with *Pseudomonas aeruginosa* biofilms. *Microbiology* 2016;162:1755–1760.
39. Harrison F, Muruli A, Higgins S, Diggle SP. Development of an ex vivo porcine lung model for studying growth, virulence, and signaling of *Pseudomonas aeruginosa*. *Infect Immun* 2014;82:3312–3323.
40. Harrington NE, Sweeney E, Harrison F. Building a better biofilm - formation of in vivo -like biofilm structures by *Pseudomonas aeruginosa* in a porcine model of cystic fibrosis lung infection. *bioRxiv*;8585972019.
41. Meurens F, Summerfield A, Nauwynck H, Saif L, Gerdtts V. The pig: a model for human infectious diseases. *Trends Microbiol* 2012;20:50–57.
42. Williams PP, Gallagher JE. Preparation and long-term cultivation of porcine tracheal and lung organ cultures by alternate exposure to gaseous and liquid medium phases. *In Vitro* 1978;14:686–696.
43. Martineau F, Picard FJ, Ke D, Paradis S, Roy PH et al. Development of a PCR assay for identification of staphylococci at genus and species levels. *J Clin Microbiol* 2001;39:2541–2547.
44. Andrews JM. Determination of minimum inhibitory concentrations. *J Antimicrob Chemother* 2001;48:5–16.
45. Craig WA. Pharmacokinetic/Pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. *Clin Infect Dis* 1998;26:1–2.
46. Bergan T. Penicillins. *Antibiot Chemother* 1971;1978:1–122.
47. Vanhomerig E, Moons P, Pirici D, Lammens C, Hernalsteens JP et al. Comparison of biofilm formation between major clonal lineages of methicillin resistant *Staphylococcus aureus*. *PLoS One* 2014;9:e104561.
48. Goerke C, Wolz C. Adaptation of *Staphylococcus aureus* to the cystic fibrosis lung. *Int J Med Microbiol* 2010;300:520–525.
49. Smyth A. Update on treatment of pulmonary exacerbations in cystic fibrosis. *Curr Opin Pulm Med* 2006;12:440–444.
50. DePas WH, Starwalt-Lee R, Van Sambeek L, Ravindra Kumar S, Gradinaru V et al. Exposing the three-dimensional biogeography and metabolic states of pathogens in cystic fibrosis sputum via hydrogel embedding, clearing, and rRNA labeling. *mBio* 2016;7:e00796-16.
51. Kahl BC, Becker K, Löffler B. Clinical significance and pathogenesis of staphylococcal small colony variants in persistent infections. *Clin Microbiol Rev* 2016;29:401–427.
52. Baltimore RS, Christie CD, Smith GJ. Immunohistopathologic localization of *Pseudomonas aeruginosa* in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration. *Am Rev Respir Dis* 1989;140:1650–1661.
53. Bjarnsholt T, Jensen Peter Østrup, Fiandaca MJ, Pedersen J, Hansen CR et al. *Pseudomonas aeruginosa* biofilms in the respiratory tract of cystic fibrosis patients. *Pediatr Pulmonol* 2009;44:547–558.
54. Henderson AG, Ehre C, Button B, Abdullah LH, Cai LH et al. Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. *J Clin Invest* 2014;124:3047–3060.
55. Potts SB, Roggli VL, Spock A. Immunohistologic quantification of *Pseudomonas aeruginosa* in the tracheobronchial tree from patients with cystic fibrosis. *Pediatr Pathol Lab Med* 1995;15:707–721.
56. de Jong PA, Nakano Y, Lequin MH, Mayo JR, Woods R et al. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. *Eur Respir J* 2004;23:93–97.
57. Dovey M, Wissemann CL, Roggli VL, Roomans GM, Shelburne JD et al. Ultrastructural morphology of the lung in cystic fibrosis. *J Submicrosc Cytol Pathol* 1989;21:521–534.
58. Sawai T, Tomono K, Yanagihara K, Yamamoto Y, Kaku M et al. Role of coagulase in a murine model of hematogenous pulmonary infection induced by intravenous injection of *Staphylococcus aureus* enmeshed in agar beads. *Infect Immun* 1997;65:466–471.
59. Hirschhausen N, Block D, Bianconi I, Bragonzi A, Birtel J et al. Extended *Staphylococcus aureus* persistence in cystic fibrosis is associated with bacterial adaptation. *Int J Med Microbiol* 2013;303:685–692.
60. Madhani K, McGrath E, Gugliani L. A 10-year retrospective review of pediatric lung abscesses from a single center. *Ann Thorac Med* 2016;11:191–196.
61. Elizur A, Orscheln RC, Ferkol TW, Atkinson JJ, Dunne WM et al. Panton-Valentine leukocidin-positive methicillin-resistant *Staphylococcus aureus* lung infection in patients with cystic fibrosis. *Chest* 2007;131:1718–1725.
62. Lester LA, Egge A, Hubbard VS, Di Sant' Agnese PA. Aspiration and lung abscess in cystic fibrosis. *Am Rev Respir Dis* 1983;127:786–787.
63. Goss CH, Muhlebach MS. Review: *Staphylococcus aureus* and MRSA in cystic fibrosis. *J Cyst Fibros* 2011;10:298–306.
64. Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P et al. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. *Nat Rev Microbiol* 2006;4:295–305.
65. Davies D. Understanding biofilm resistance to antibacterial agents. *Nat Rev Drug Discov* 2003;2:114–122.
66. Kriegeskorte A, Grubmüller S, Huber C, Kahl BC, von Eiff C et al. *Staphylococcus aureus* small colony variants show common metabolic features in central metabolism irrespective of the underlying auxotrophism. *Front Cell Infect Microbiol* 2014;4:141.
67. Sifri CD, Baresch-Bernal A, Calderwood SB, von Eiff C. Virulence of *Staphylococcus aureus* small colony variants in the *Caenorhabditis elegans* infection model. *Infect Immun* 2006;74:1091–1096.
68. Ou JJJ, Drilling AJ, Cooksley C, Bassiouni A, Kidd SP et al. Reduced innate immune response to a *Staphylococcus aureus* small colony

variant compared to its wild-type parent strain. *Front Cell Infect Microbiol* 2016;6:187.

69. Tuchscher L, Medina E, Hussain M, Völker W, Heitmann V et al. *Staphylococcus aureus* phenotype switching: an effective bacterial strategy to escape host immune response and establish a chronic infection. *EMBO Mol Med* 2011;3:129–141.

70. Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. *Clin Microbiol Rev* 2010;23:299–323.

Edited by: J. Stülke and E. L Denham

Five reasons to publish your next article with a Microbiology Society journal

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as 'excellent' or 'very good'.
5. Your article will be published on an interactive journal platform with advanced metrics.

Find out more and submit your article at microbiologyresearch.org.